Literature DB >> 8054279

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.

S Romain1, O Chinot, J G Klijn, W L van Putten, O Guirou, M Look, P M Martin, J A Foekens.   

Abstract

Tyrosine-specific protein kinase (TPK) has been associated with the cytoplasmic domain of growth factor receptors as well as oncoproteins. Enzymatic activation appears to be a major initial event in these signal transduction pathways. In this study, TPK was determined in the cytosols of 249 node-positive primary breast tumours. Enzyme activity was measured using [32P]ATP and poly(glutamic acid-tyrosine) (4:1) as an artificial substrate. Levels of TPK varied from 0 to 35.9 pmol ATP min-1 mg-1 protein (median 11.4). No correlation was found with tumour size or number of positive lymph nodes. In contrast, levels of TPK were negatively associated with age (P = 0.01) and menopausal status (P < 0.05) of the patients. Higher concentrations of TPK were in addition found in tumours negative for oestradiol (P < 0.01) and progesterone (P < 0.05) receptors. Finally, a positive correlation was found between TPK and urokinase plasminogen activator (UPA) (P < 0.05). Patients whose tumours contained high levels of TPK had reduced disease-free (P = 0.01) and overall survival (P < 0.05). In Cox multivariate analysis, including patient's age, menopausal status, tumour size, number of positive lymph nodes, steroid receptors and UPA, TPK retained its independent prognostic importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8054279      PMCID: PMC2033501          DOI: 10.1038/bjc.1994.297

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

Review 1.  Oncogenes and signal transduction.

Authors:  L C Cantley; K R Auger; C Carpenter; B Duckworth; A Graziani; R Kapeller; S Soltoff
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 2.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

3.  Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue.

Authors:  A Hennipman; B A van Oirschot; J Smits; G Rijksen; G E Staal
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

Review 4.  Growth factors in the regulation of pericellular proteolysis: a review.

Authors:  M Laiho; J Keski-Oja
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

Review 5.  Insulin-like growth factor 1 receptors (IGF1-R) and IGF1 in human breast tumors.

Authors:  J P Peyrat; J Bonneterre; P H Vennin; H Jammes; R Beuscart; B Hecquet; J Djiane; J Lefebvre; A Demaille
Journal:  J Steroid Biochem Mol Biol       Date:  1990-12-20       Impact factor: 4.292

6.  Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

Authors:  J A Foekens; H Portengen; W L van Putten; A M Trapman; J C Reubi; J Alexieva-Figusch; J G Klijn
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.

Authors:  M Bolla; B R Rostaing-Puissant; M Chedin; C Souvignet; J Marron-Charriere; M Colonna; E Berland; E M Chambaz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.

Authors:  M J Niedbala; A C Sartorelli
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

10.  The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers.

Authors:  A Dvir; Y Milner; O Chomsky; C Gilon; A Gazit; A Levitzki
Journal:  J Cell Biol       Date:  1991-05       Impact factor: 10.539

View more
  2 in total

1.  Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.

Authors:  M Bolla; B Rostaing-Puissant; S P Bottari; M Chedin; J Marron-Charriere; M Colonna; E Berland; E Chambaz
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 2.  Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Authors:  Haroon A Hussain; Amanda J Harvey
Journal:  World J Clin Oncol       Date:  2014-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.